News & Updates

Individuals with worsening chronic kidney disease (CKD) are at greater risk for emergently treated hypocalcemia with denosumab, and the highest risk is observed among dialysis-dependent (DD) patients and those with CKD–mineral and bone disorder (CKD-MBD), reveals a study.

Treatment with budesonide/glycopyrrolate/formoterol (BGF) using a metered dose inhaler (MDI) demonstrates an acceptable safety profile and improves symptoms in patients with chronic obstructive pulmonary disease (COPD) in a real-world clinical setting, results of the TORES study have shown.